# Darbepoetin Alfa With or Without Intravenous (IV) Iron

> **NCT00401544** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 243 (actual)

## Conditions studied

- Anemia
- Non-Myeloid Malignancies

## Interventions

- **DRUG:** darbepoetin alfa
- **DRUG:** IV iron dextran

## Key facts

- **NCT ID:** NCT00401544
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-12
- **Final completion:** 2008-03
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401544, "Darbepoetin Alfa With or Without Intravenous (IV) Iron". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00401544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*